Megan Hollasch

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication OncologyLive, aiding in all aspects of the publication process, as well as content for OncLive.com.

Articles

Notable RCC Data Presented at ASCO May Shed Light on Key Biomarkers and Combination Approaches

June 7th 2024

Benjamin L. Maughan, MD, PharmD, dives into key studies in RCC regarding biomarkers and first-line treatments presented at the 2024 ASCO Annual Meeting

Advancements With Combination Therapies in RCC Usher in New Questions

June 6th 2024

Benjamin L. Maughan, MD, PharmD, discusses the implications of immuno-oncology and TKI agent combinations in clear cell and non–clear cell RCC.

Higher T-Cell Inflamed GEP Values Are Positively Associated with Outcomes For Pembrolizumab/Axitinib in ccRCC

June 5th 2024

Higher T-cell inflamed GEP values were positively associated with clinical outcomes for pembrolizumab plus axitinib in advanced clear cell RCC.

A Geneticist and PCP Detail Considerations With New Screening Recommendations for Breast Cancer

June 5th 2024

Brittany L. Bychkovsky, MD, MSc, and Lydia Pace, MD, MPH, explain approaches to breast cancer screening and considerations with the final USPSTF screening recommendations.

Lenvatinib/Pembrolizumab Yields Greater Clinical Benefit vs Sunitinib Regardless of Biomarker Subtypes in ccRCC

June 3rd 2024

Lenvatinib plus pembrolizumab displayed a superior clinical benefit vs sunitinib irrespective of patient biomarker subtype in advanced clear cell RCC.

mIF Biomarker Not Associated With Improved Outcomes With Nivolumab/Ipilimumab Treatment in Metastatic Clear Cell RCC

June 2nd 2024

Using CD8-positive, PD-1-positive, TIM3-negative, and LAG3-negative TILs as a biomarker was not associated with improved clinical outcomes for patients with mccRCC treated with nivolumab plus ipilimumab.

Taletrectinib Yields Durable Responses in TKI Naive and Crizotinib Pretreated ROS1+ NSCLC

June 2nd 2024

Taletrectinib demonstrated high response rates and a tolerable safety profile in patients with ROS1-positive non–small cell lung cancer.

Lorlatinib Yields Longest Reported PFS in Advanced ALK+ NSCLC

May 31st 2024

Lorlatinib extended PFS and improved time to intracranial progression vs crizotinib in patients with ALK-positive non–small cell lung cancer.

Recent Data Shed Further Light on the MDS Treatment Paradigm as the SOC Evolves

May 30th 2024

Jeremy Allred, MD, details current and emerging treatments for patients with myelodysplastic syndrome, highlighting recent key data updates.

Tovorafenib Offers an Efficacious Option for R/R BRAF-Positive Pediatric Low-Grade Glioma

May 28th 2024

Sarah ES Leary, MD, MS, details the significance of the FDA-approval of tovorafenib for patients with relapsed or refractory BRAF-positive pediatric low-grade glioma.

Vanderbilt Symposium Highlights Recent Data on Novel Agents Under Evaluation in Hematologic Malignancies

May 24th 2024

Katie S. Gatwood, PharmD, BCOP, explains next steps with novel agents in the hematologic oncology field that have the potential to change practice.

Narayan Discusses Bladder Preservation and the Role of Gene Therapies in NMIBC

May 23rd 2024

Vikram M. Narayan, MD, highlights takeaways from 5-year follow-up data examining the gene therapy nadofaragene firadenovec and details promising emerging therapies for bladder cancer.

Eckfeldt Looks Towards the Future of AML and MDS Care

May 22nd 2024

Craig Eckfeldt, MD, PhD, discusses key updates in the MDS treatment paradigm and the implications of MRD testing, as well as next steps in the field of AML.

First-in-Class PARP1 Selective Inhibitor Saruparib Shines in Phase 1 Trial of Advanced Solid Tumors

May 21st 2024

Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated.

Mirvetuximab Soravtansine Plus Pembrolizumab Generates Reponses in pMMR FRα+ Serous Endometrial Cancer

May 20th 2024

Rebecca Porter, MD, PhD, discusses mirvetuximab soravtansine plus pembrolizumab in serous endometrial cancer and future directions for ADCs in the space.

BTK Inhibitor Combinations Move to Forefront of CLL Investigations, Conversations

May 20th 2024

Mazyar Shadman, MD, MPH, details the efficacy of BTK inhibitors in the frontline treatment of CLL as well as safety considerations in the relapsed/refractory setting.

Real-World Study Sheds Light on Treatment Sequences and Second-Line Outcomes in HER2+ Breast Cancer

May 19th 2024

A real-world study dives into treatment sequencing data and indicates most patients with HER2-positive metastatic breast cancer discontinued second-line treatment in the US.

The AACR Releases a Call to Action and Key Statistics in Cancer Disparities Progress Report 2024

May 18th 2024

The AACR issues a call to action and cites progress, needed improvements, and key statistics in their Cancer Disparities Progress Report 2024.

Telemedicine Allows for First-of-its-Kind Trial Administering Subcutaneous Immunotherapy at Home

May 17th 2024

Jorge J. Nieva, MD, details the benefits of telemedicine and a first-of-its-kind clinical trial where patients with NSCLC will receive subcutaneous immunotherapy at home.

Updated Breast Cancer Screening Recommendations Pave the Way for a More Equitable Future

May 16th 2024

Carol M. Mangione, MD, discusses the ramifications of the US Preventative Task Force’s April decision to update the breast cancer screening guidelines.